Related Experiment Video
Updated: Jan 27, 2026
Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
Published on: May 17, 2018
Role of Poly (ADP-Ribose) Polymerase-1 (PARP1) and Its Inhibitors for Cancer Therapy
Mettu Omkar Bala Narasimha1, Hardha Balachandran1, Byran Gowramma1
1Department of Pharmaceutical Chemistry, JSS Academy of Higher Education & Research, JSS College of Pharmacy, Ooty, Nilgiris, Tamil Nadu, India.
Introduction:
Poly (ADP-ribose) polymerase (PARP) regulates transcription, replication, DNA repair, and the cell cycle. This study examines the multiple functions of PARP beyond DNA repair, including its role in immunological modulation, chemokine signaling, and the regulation of gene expression, particularly during angiogenesis and the epithelial-to-mesenchymal transition.
Methods:
PARP inhibitors are approved for treating malignancies by targeting vulnerabilities associated with homologous recombination (HR) insufficiency, such as that caused by BRCA1/2 malfunction. By contrasting the "double-strand break (DSB)" and "single-stranded DNA (ssDNA) gap" models of synthetic lethality, PARP inhibitors are used to treat BRCA1/2-deficient cancers. We examine how ssDNA gaps and DNA polymerase theta (POLθ) interact to influence treatment outcomes.
Results:
This review highlights that advanced research is required to bridge the gap between laboratory models and real-world scenarios, focusing on the therapeutic implications of PARP1 efficacy and resistance mechanisms in BRCA-mutated cancers.
Discussion:
PARP inhibitors extend beyond DNA repair, with ssDNA gap-driven lethality and POLθ- mediated resistance shaping efficacy, clinical translation, and emerging roles in metastasis prevention.
Conclusion:
With an emphasis on specific metastatic sites and PARP-selective inhibitors, we conclude by highlighting recent clinical developments in PARP inhibitors for the prevention and treatment of distant metastases. Because of their promising results in preventing metastatic cancer, PARP inhibitors may be used more frequently in the early stages of cancer.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibitors show promise in treating BRCA-mutated cancers by exploiting DNA repair deficiencies. Further research is needed to optimize their use, especially in preventing and treating cancer metastases.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Poly (ADP-ribose) polymerase (PARP) regulates critical cellular processes including transcription, DNA repair, and cell cycle progression.
- This study investigates PARP's diverse functions beyond DNA repair, encompassing immunological modulation, chemokine signaling, and gene expression regulation during angiogenesis and epithelial-to-mesenchymal transition.
Purpose of the Study:
- To explore the multifaceted roles of PARP in cellular functions and cancer biology.
- To examine the mechanisms of synthetic lethality involving PARP inhibitors, DNA repair pathways (like homologous recombination), and specific genetic mutations (BRCA1/2).
- To review the therapeutic implications of PARP inhibitors, including efficacy, resistance, and clinical developments in cancer treatment.
Main Methods:
- Analysis of the synthetic lethality models, specifically contrasting the double-strand break (DSB) and single-stranded DNA (ssDNA) gap mechanisms.
- Investigation of the interaction between ssDNA gaps and DNA polymerase theta (POLθ) in determining treatment outcomes.
- Review of current research on PARP inhibitor efficacy and resistance in BRCA-mutated cancers.
Main Results:
- PARP inhibitors are clinically approved for malignancies with homologous recombination (HR) insufficiency, such as BRCA1/2-deficient cancers.
- Understanding the interplay between ssDNA gaps and POLθ is crucial for optimizing PARP inhibitor therapy.
- Significant research is needed to translate laboratory findings into clinical practice, focusing on PARP1 efficacy and resistance in BRCA-mutated cancers.
Conclusions:
- Recent clinical advancements show PARP inhibitors are effective in preventing and treating distant metastases, suggesting earlier clinical application.
- PARP-selective inhibitors and targeted strategies for specific metastatic sites are key areas of development.
- PARP inhibitors hold significant potential for early-stage cancer intervention and management of metastatic disease.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
00:43Bacterial RNA Polymerase
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:42The ADP/ATP Carrier Protein
02:10Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...